

## UNITED STES DEPARTMENT OF COMMERCE Patent and Trademark Office

COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

| EMP <sub>RO</sub>  | Address:         | Washington, D.C. 20231 | ATTORNEY DOCKET NO.   |
|--|------------------|------------------------|-----------------------|
| T-WO DATE  | FIRST NAMED INVE | NTOR                   | 李相盖的一个 <u>是特</u> 能的是一 |
| APPLICATION NO. FILING DATE  | and the Halles   | 7                      | EXAMINER              |
| _  | epit2 theid      | STATE ART U            | DAPPH NO              |
| Education and Obstantional Construction of Estate and Construction of Construc |                  | DATE MAI               |                       |
| Fig. 1. A. A. A.   |                  |                        |                       |

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

1- File Copy PTO-90C (Rev. 2/95)





#### S DEPARTMENT OF COMMERCE UNITED ST demark Office Patent and

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

|                  | ATES OT   | 11055                | ·        |  |
|------------------|-----------|----------------------|----------|--|
|                  |           | FIRST NAMED APPLICAN | Т        | ATTORNEY DOCKET NO.  |
| SERIAL NUMBER FI | LING DATE | FIROT NAME           |          | THE PART OF THE PA |
|                  |           |                      |          | EXAMINER   |
|                  |           | [                    | ART UNIT | PAPER NUMBER   |
|                  |           |                      |          | 9  |
|                  |           |                      |          |  |

DATE MAILED:

### Please find below a communication from the EXAMINER in charge of this application.

#### Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the Applicant is given ONE MONTH, or THIRLT DATS, whichever is longer, from the mailing date or this letter within which to comply sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 sequence rules, 37 OFK 1.021 - 1.025. Failure to comply with these requirements will result in ADANDONMENT of the application under 37 CFR 1.136(a). In CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In OFK 1.021(g). Extensions of time may be obtained by fitting a petition accompanied by the extension fee under the provisions of 37 OFK 1.130(g) no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Pak, whose telephone number is (703) 305-7038. The examiner can normally be reached on Monday

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Paula Hutzell, through Friday from 9:30 AM to 6:00 PM.

Official papers filed by fax should be directed to (703) 308-4242. Faxed draft or informal communications can be reached on (703) 308-4310. with the examiner should be directed to (703) 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Michael D. Por Michael Pak Patent Examiner

Art Unit 1646 17 June 1999

# Application No.: 09/226,046 NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

| g reason(s):   | Applicant's            |
|--|------------------------|
| g reason(s).  g reason(s).  1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825.  1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825.   | at 55 FR               |
| 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.020.  attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and a attention is directed to these regulations.   | 11.00                  |
| Aftention is directed to a   |                        |
| 18230, May 1, 1990.  | a "Sequence            |
| 18230, May 1, 1990.  2. This application does not contain, as a separate part of the disclosure on paper copy, a contain, as a separate part of the disclosure on paper copy, a contain, as a separate part of the disclosure on paper copy, a contain, as a separate part of the disclosure on paper copy, a contain, as a separate part of the disclosure on paper copy, a contain, as a separate part of the disclosure on paper copy, a contain, as a separate part of the disclosure on paper copy, a contain, as a separate part of the disclosure on paper copy, a contain, as a separate part of the disclosure on paper copy, a contain, as a separate part of the disclosure on paper copy, a contain, as a separate part of the disclosure on paper copy, a contain, as a separate part of the disclosure on paper copy, a contain, as a separate part of the disclosure on paper copy, a contain, as a separate part of the disclosure on paper copy, a contain, as a separate part of the disclosure on paper copy, a contain a c |                        |
| 2. This application does not contain.  Listing" as required by 37 C.F.R. 1.821(c).   | · d by                 |
| Listing" as required by 37 C.F.R. 1.02 ((o))  Listing" as required by 37 C.F.R. 1.02 ((o))  3. A copy of the "Sequence Listing" in computer readable form has not been submitted a   | s required by          |
| A conv of the "Sequence Listing" in computer readable 1911   |                        |
| 37 C.F.R. 1.02 (0).  | wever the              |
| histing" in computer readable form has been submitted. The   | C.F.R. 1.822           |
| 4. A copy of the "Sequence Listing "Form does not comply with the requirements of the "Raw Sequence Listing "R | sting."                |
| content of the company the attached copy of the marked of  |                        |
| and/or 1.823, as indicated on the attached corpy and/or 1.823, as indicated on the attached with this application has been found  5. The computer readable form that has been filed with this application has been found  to the computer readable as indicated on the attached CRF Diskette Problem Report. A Survivor of the computer of the | to be damaged          |
| 5. The computer readable form that has been filed with this application has been floated and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Su and/or unreadable form must be submitted as required by 37 C.F.R. 1.825(d).  | ibstitute              |
| and/or unreadable as indicated on the attached of the authority and an analysis and a submitted as required by 37 C.F.R. 1.825(d).   |                        |
| 5. The computer readable form the attached CRF Diskette Problem 1.825(d). and/or unreadable as indicated on the attached CRF Diskette Problem 1.825(d). computer readable form must be submitted as required by 37 C.F.R. 1.825(d).  | from of the            |
| Listing" is not the same as the computer reason  |                        |
| computer readable form must be substitute.  6. The paper copy of the "Sequence Listing" is not the same as the computer readable "Sequence Listing" as required by 37 C.F.R. 1.821(e).   |                        |
| Sequence Listing as require  |                        |
| 7 Other  |                        |
| 7. Other:  |                        |
| _  |                        |
| Applicant Must Provide:  An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".   |                        |
| Approvation or substitute computer readable form (CRF) copy of the   |                        |
| X An initial of Subserve   | ita antri              |
| atti. "Componed Listing", as well as an amendme  | nt directing its entry |
| An initial or substitute paper copy of the "Sequence Listing", as well as an amendmental An initial or substitute paper copy of the "Sequence Listing", as well as an amendmental and the sequence Listing as well as an amendmental and the sequence Listing as well as an amendmental and the sequence Listing as well as an amendmental and the sequence Listing as well as an amendmental and the sequence Listing as well as an amendmental and the sequence Listing as well as an amendmental and the sequence Listing and the sequence Listing as well as an amendmental and the sequence Listing and the seq |                        |
| into the specification.  | ne and, where          |
| into the specification.  A statement that the content of the paper and computer readable copies are the sar applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(f) or 1.825(d)   | 1.821(g) or            |
| A statement that the content of the paper.   |                        |
| applicable, include the  |                        |
| 1.825(b) or 1.825(d).  | act:                   |
| 1.825(b) or 1.825(d).  1.825(d) or 1.825(d).  For questions regarding compliance to these requirements, please contains and (703) 308-4216   |                        |
|  |                        |
| For Rules Interpretation, call (703) 308-4216 For Rules Interpretation, call (703) 308-4212  |                        |
| For CRE SUDMISSION NOTE STORY AND GOES   | TOPONSE                |
| For Patentin software help, call (703) 308-8656  | (E2LON2E               |

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE